Edition:
United Kingdom

Audentes Therapeutics Inc (BOLD.OQ)

BOLD.OQ on NASDAQ Stock Exchange Global Market

36.72USD
23 May 2018
Change (% chg)

$-1.20 (-3.16%)
Prev Close
$37.92
Open
$37.27
Day's High
$37.63
Day's Low
$36.54
Volume
83,539
Avg. Vol
139,919
52-wk High
$42.50
52-wk Low
$14.06

Chart for

About

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the... (more)

Overall

Beta: --
Market Cap(Mil.): $722.67
Shares Outstanding(Mil.): 27.78
Dividend: --
Yield (%): --

Financials

  BOLD.OQ Industry Sector
P/E (TTM): -- 84.06 32.75
EPS (TTM): -3.54 -- --
ROI: -57.99 1.57 14.38
ROE: -145.70 2.43 16.07

BRIEF-Audentes Announces Data From First Dose Cohort Of ASPIRO

* AUDENTES ANNOUNCES CONTINUING POSITIVE DATA FROM FIRST DOSE COHORT OF ASPIRO, A PHASE 1/2 CLINICAL TRIAL OF AT132 IN PATIENTS WITH X-LINKED MYOTUBULAR MYOPATHY

16 May 2018

BRIEF-Audentes Therapeutics Reports Qtrly Loss Per Share $0.74

* AUDENTES THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

09 May 2018

BRIEF-Audentes Therapeutics CEO Matthew Patterson's 2017 Total Compensation Was $6.9 Million

* AUDENTES THERAPEUTICS INC SAYS CEO MATTHEW PATTERSON'S 2017 TOTAL COMPENSATION WAS $6.9 MILLION – SEC FILING Source text for Eikon: (http://bit.ly/2KknZ9F) Further company coverage:

27 Apr 2018

BRIEF-Audentes Therapeutics Q4 Loss Per Share ‍$0.82

* AUDENTES THERAPEUTICS REPORTS FOURTH QUARTER 2017 AND FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

08 Mar 2018

BRIEF-Wellington Management Group Llp Reports 10.85 pct Passive Stake In Audentes Therapeutics As Of Jan 31, 2018

* WELLINGTON MANAGEMENT GROUP LLP REPORTS 10.85 PERCENT PASSIVE STAKE IN AUDENTES THERAPEUTICS INC AS OF JANUARY 31, 2018 - SEC FILING‍​ Source text - (http://bit.ly/2nZykxi) Further company coverage:

12 Feb 2018

BRIEF-Audentes Therapeutics Says Public Offering Of 5.75 Mln Shares Priced At $35/Share

* AUDENTES THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

25 Jan 2018

BRIEF-Audentes Therapeutics To Offer $150 Million Of Common Stock In Public Offering​

* AUDENTES THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

23 Jan 2018

BRIEF-Audentes Announces Positive Interim Data From First Dose Cohort Of Aspiro

* AUDENTES ANNOUNCES POSITIVE INTERIM DATA FROM FIRST DOSE COHORT OF ASPIRO, A PHASE 1/2 CLINICAL TRIAL OF AT132 IN PATIENTS WITH X-LINKED MYOTUBULAR MYOPATHY

04 Jan 2018

Competitors

  Price Chg
Amicus Therapeutics, Inc. (FOLD.OQ) $15.16 -0.38
Sanofi SA (SASY.PA) €66.23 -0.14

Earnings vs. Estimates